In several studies with neoepitopes, a CD8 response, as measured by ELISPOT or flow cytometry, is indeed associated with tumor control in vivo (25, 27, 28), supporting the idea that the CD8+ T responses, as measured by ELISPOT or flow cytometry, are surrogates of antitumor efficacy in vivo. This evidence concerns the gene CD8A and neoplasm.